EARLY TAVR Trial Sends Clear Message: “Don’t Wait”!
EARLY TAVR Trial Sends Clear Message: “Don’t Wait”!
New TAVR Data Challenges the Wait-and-See policy-
(“watchful waiting” or clinical monitoring):
EARLY TAVR Trial Highlights – Published May 1, 2025
Presented at ACC.25
1. Early TAVR in asymptomatic severe aortic stenosis (AS) patients leads to significantly better outcomes than waiting for symptoms to appear.
2. Among patients who followed a “wait-for-symptoms” strategy, 40% deteriorated rapidly and unpredictably. These patients often presented with:
• Sudden cardiac arrest
• Acute heart failure or pulmonary edema
• Significantly higher stroke rates
3. Delayed intervention resulted in worse clinical outcomes, including:
• Increased mortality
• More unplanned hospitalizations
• Higher post-TAVR instability and complications
4. The trial enrolled ~900 asymptomatic patients, split between early TAVR and standard monitoring. Long-term data confirmed that early TAVR outperformed symptom-guided timing across all major endpoints.
5. Waiting can be dangerous:
• “Crash and burn” patients progressed from stable to critically ill within months.
• Once symptomatic, these patients were harder to treat, and less likely to recover fully.
6. Risk prediction during watchful waiting is unreliable:
• Conventional tools (valve velocity, LVEF, stress testing) failed to identify which patients would suddenly deteriorate.
• Many patients appeared stable until they weren’t.
7. Stroke risk nearly doubled in the delayed group, particularly after 2 years. Severe AS may independently contribute to stroke through mechanisms such as:
• Progressive valve calcification
• Occult atrial fibrillation
• Inflammatory and thrombotic changes
8. Dr. Philippe Genereux, the principal investigator, emphasized:
“You can’t predict who will crash. That’s why waiting is a gamble—with 40% odds of serious decline.”
He added: “It’s time to change the guidelines and act earlier.”
9. These findings helped support the FDA’s May 1, 2025 approval of the Edwards Sapien 3 valve for asymptomatic severe AS patients, marking a shift in how early disease is managed.
Link :
Article: Latest EARLY TAVR data suggest it is time to update industry guidelines
